Tahoe Therapeutics is a biotechnology company founded in 2022 that builds computational platforms for drug discovery. The firm's core technology, the Mosaic platform, generates gigascale single-cell maps to measure how drug molecules interact with patient-derived cells. This approach produces hundreds of millions of data points mapping drug-biology interactions at high resolution.
The company's products include Tahoe-100M, described as the world's largest single-cell atlas, containing 100 million single-cell data points and 60,000 drug-patient interactions - 50 times larger than all public perturbative single-cell data combined. Another product, Tahoe-x1, is a 3-billion-parameter foundation model that learns unified representations of genes, cells, and drugs, achieving state-of-the-art performance in cancer-relevant biology benchmarks.
Tahoe Therapeutics works across machine learning, genomics, cancer biology, single-cell analysis, and foundation models. The company was founded by scientists and technologists with backgrounds from institutions including Princeton, UCSF, and UC Berkeley.
